Cogent Biosciences (NASDAQ:COGT) reported quarterly losses of $(0.53) per share which beat the analyst consensus estimate of $(0.56) by 5.36 percent. This is a 1.92 percent decrease over losses of $(0.52) per share from the same period last year.